NDASUBLINGUALTABLET
Approved
Dec 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ISORDIL (isosorbide dinitrate) by Thayer Medical is clinical pharmacology the principal pharmacological action of isosorbide dinitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. First approved in 1961.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISORDIL (isosorbide dinitrate) is an organic nitrate that relaxes vascular smooth muscle to dilate peripheral arteries and veins, reducing cardiac preload and afterload. It is indicated for heart failure management via sublingual tablet administration. The drug works by promoting peripheral blood pooling and decreasing venous return to the heart, thereby reducing left ventricular pressure.
LOE Approaching
Product approaching end-of-life with minimal linked job openings; likely consolidated brand team focused on transition planning and generic competition management.
Mechanism of Action
CLINICAL PHARMACOLOGY The principal pharmacological action of isosorbide dinitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to…
Worked on ISORDIL at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.